A clinical stage biopharmaceutical company applying our pioneering DARPinŽ product candidates to treat serious diseases, with a current focus on infectious disease, oncology and ophthalmology. Our DARPin platform, which is designed using ankyrin repeat proteins, allows us to build product candidates with multiple mechanisms of action to address complex biological problems, while potentially offering patients products with higher efficacy and fewer adverse events. We believe that DARPin therapeutics represent a novel class of drugs with broad therapeutic applications that may overcome many of the limitations of conventional protein and antibody-based therapeutics.
Lead Underwriter
Cowen and Company, LLC, J.P. Morgan Securities LLC, SVB Leerink LLC
